It was a great pleasure to meet with Prof. Paul Heath (St George’s, University of London, London, UK) to discuss the findings from the Phase III Novavax clinical trial that is investigating the safety and efficacy of NVX-CoV2373, a vaccine candidate for COVID-19. Please find Part 2 of this interview available here.
To access more COVID-19 content, please visit our COVID-19 Hub.
Questions:
- What is the design of the Novavax vaccine, and how is it stored and administered? (0:25)
- Could you give us a brief overview of the Phase III Novavax clinical trial? (2:03)
- What were the safety findings of the study? (8:02)
- What questions remain unanswered about the vaccine efficacy and safety? (10:19)
Disclosures: Paul Heath has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
